What are the opening hours?

Monday 08:30 - 17:30 Tuesday 08:30 - 17:30 Wednesday 08:30 - 17:30 Thursday 08:30 - 17:30 Friday 08:30 - 17:30

Kexing Biopharm Co.,Ltd.

Home
China
Jinan
Kexing Biopharm Co.,Ltd.

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Kexing Biopharm Co.,Ltd., Medical and health, The 31 floor，Huarun Center building，Lixia District, Jinan.

Kexing Biopharm is dedicated to creating innovative medicines - from proteins to cell & gene therapies - to fight cancer, autoimmune & infectious diseases and improve patients lives worldwide.

29/09/2025

🎉 Kexing Biopharm’s In-licensed Sorafenib Generic Approved in Peru via “Green Channel” 🎉

✌ Following its recent approval in Egypt, the Sorafenib Tosylate Tablets generic, in-licensed by Kexing Biopharm from Yabao Pharmaceutical Co., Ltd. Beijing, has been approved for marketing by Peru’s National Authority of Medicines and Medical Devices (DIGEMID) through its “green channel” expedited review pathway.

✅ Sorafenib, as a well-recognized molecular targeted therapy, is indicated for the treatment of liver cancer, renal cancer, and thyroid cancer. The accelerated approval in Peru further strengthens Kexing Biopharm’s market presence in Latin America and aligns with the company’s broader strategy of expanding access to oncology and specialty medicines worldwide.

🌏 Kexing Biopharm is actively building a “Global Selection, Global Coverage” commercialization platform, open to collaboration with leading enterprises. Driven by innovation, the company is committed to improving treatment accessibility for patients around the world.

28/09/2025

✅Initiation of Phase Ia Clinical Trial in China for Innovative Pipeline: GB18

🎯Recently, the GB18 pipeline, independently developed by Kexing Biopharm, has officially entered Phase Ia clinical trial in China. Healthy volunteers will be recruited in Phase Ia where a single ascending dose design is utilized to primarily evaluate the drug's safety, tolerability, and pharmacokinetic profiles in human.

🔍Not long ago, the GB18 program received approvals for clinical trial development in China and the United States, respectively, positioning it as one of the key pipelines with dual regulatory filings to FDA and NMPA.

💪As an innovative therapeutic drug targeting GDF15, GB18 harnesses its distinctive nanobody architecture and is intended for the treatment of cancer cachexia. Its mechanism of action precisely inhibits the aberrant activation of the GDF15-GFRAL-RET signaling pathway, thereby significantly ameliorating symptoms such as anorexia and associated metabolic disruptions in cancer patients; preclinical animal studies have demonstrated that GB18 effectively mitigates weight loss, restores muscle integrity, and enhances physical performance.

👏A pervasive condition among patients with various advanced malignancies, cancer cachexia not only profoundly impairs energy balance, physical function but also significantly and negatively impacts a patient’s prognosis and overall quality of life. Effective therapeutic interventions of cancer cachexia remain a critical unmet clinical need.

✅Moving forward, Kexing will proactively advance the clinical development of the GB18 program.

24/09/2025

🎉 Pediatric RSV(GB05) Therapy Accepted into CDE Breakthrough Treatment Program

💪 Kexing Biopharm’s investigational therapy, interferon alpha-1b inhalation solution (GB05 project), has been included in the breakthrough treatment program of China’s Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), and publicly announced.

✅ This therapy is designed specifically for children to treat lower respiratory tract infections caused by respiratory syncytial virus (RSV), such as pneumonia and bronchiolitis. Currently, there is no widely available antiviral drug for infants with RSV infections. GB05 aims to help address this unmet medical need and, once approved, may become the world’s first interferon-based inhalation therapy for pediatric RSV.

✅ Compared with injections, the inhalation solution is delivered via nebulization directly to the respiratory tract, enabling faster onset while avoiding injection-related discomfort. This approach improves treatment acceptance and safety for young patients.

✅ Being recognized under the breakthrough treatment program provides priority resources and guidance during the development and review process, which may accelerate clinical advancement.

🌍 Kexing Biopharm will continue its research in antiviral, oncology, and immunology fields, exploring new therapies and expanding its global pipeline.

19/09/2025

Why does a little gecko represent Kexing Biopharm? 🦎

Because it heals itself after injury, symbolizing the ’self-healing power’ of biopharmaceuticals.

Because it moves with agility and sharp awareness, just like our ability to understand and respond to patient needs.

Because it regenerates, reminding us of new beginnings—and the hope of renewed health we strive to bring to patients.

At Kexing, we believe the future of medicine is not only about curing disease, but also about igniting hope.

16/09/2025

🎉Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF

✅Kexing Biopharm that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.

🎯Exosomes are next-generation bioactive carriers with advantages such as low immunogenicity, high pe*******on, and targeting potential. Their applications span drug delivery, regenerative medicine, and consumer healthcare.

🔍This achievement builds on Kexing’s K’Exosome platform, which enables GMP-grade, end-to-end exosome production with core strengths in purity, efficiency, and stability, as well as engineered capabilities for protein/nucleic acid loading and targeted modification. Several exosome-based R&D programs are also in progress.

🌏Kexing Biopharm will continue to advance its “Innovation + Internationalization” strategy, driving the global development and application of exosome technologies and delivering high-quality solutions for broader healthcare needs.

12/09/2025

💪Expanding Global Reach｜Kexing Biopharm Partners with Uni-Bio Science Group

👉Kexing Biopharm has announced a partnership with Uni-Bio Science Group and its subsidiary GeneTech Pharm, securing the exclusive commercialization rights of teriparatide injection (Bogutai®) in several overseas markets, including Saudi Arabia and Egypt.

✅Teriparatide is an anabolic osteoporosis therapy that promotes bone formation and is indicated for patients at high risk of fractures.

🔎With population aging accelerating worldwide, osteoporosis has become a growing public health concern. The demand for effective therapies is rising steadily, and this collaboration adds to Kexing’s portfolio in the osteoporosis field.

🌏Looking ahead, Kexing will continue to advance the global registration and commercialization of high-quality medicines, aiming to provide broader treatment options for patients worldwide.

09/09/2025

🎏Kexing Biopharm with Humanwell Puracap Pharmaceuticals have entered into a partnership to advance global commercialization of Nintedanib Esilate Soft Capsules🎏

🏆Kexing Biopharm has entered into a strategic collaboration with Humanwell Puracap Pharmaceuticals to drive the overseas commercialization of Nintedanib esilate soft capsules, marking a significant milestone in its respiratory portfolio.

✅Nintedanib is a globally recognized anti-fibrotic therapy recommended by treatment guidelines for idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and systemic sclerosis-associated ILD (SSc-ILD). As a multi-target tyrosine kinase inhibitor, it blocks multiple pathways to slow disease progression.

🌐The agreement covers global markets including the European Union market and several emerging markets. This collaboration to expands Kexing’s products portfolio.

🌏Kexing Biopharm will continue to pursue its “Global Selection + Global Coverage” strategy, accelerating the availability of innovative and high-quality medicines for patients worldwide.

08/09/2025

🎉Kexing Biopharm’s Paclitaxel for Injection (Albumin-bound) Approved in Oman🎉

💪Kexing Biopharm, in partnership with Haichang Biotech, announced that paclitaxel for injection (albumin-bound) has been approved for marketing in Oman, making it the first generic of its kind authorized in the country.

🔎As a key oncology therapy, albumin-bound paclitaxel has already achieved commercialization in the EU and multiple regions, with recognized value in treating breast, pancreatic, and non-small cell lung cancers. Compared with conventional formulations, it offers improved safety and patient compliance, earning broader clinical acceptance.

📅The approval in Oman represents a significant step in Kexing’s GCC strategy, paving the way for expansion into wider Middle Eastern. With strengthened local operations and global partnerships, Kexing is accelerating product registration and commercialization worldwide.

🌏Moving forward, Kexing Biopharm remains committed to its “Global Selection + Global Coverage” strategy, ensuring access to high-quality medicines and delivering innovative yet affordable therapies to patients globally.

05/09/2025

📍2025 Overseas Markets Pharma Export Strategy Forum｜Kexing Biopharm and Partners Explore Global Opportunities📍

🕙On the September 2nd, China Pharma Overseas Market Development Forum, Kexing Biopharm joined leading industry partners to discuss the evolving global pharmaceutical landscape, overseas market opportunities, and innovative pathways for internationalization.

🌍The forum highlighted strategies across the Middle East and Latin America, with Kexing showcasing its localized models and commercialization achievements in these regions. Kexing emphasized the importance of innovation-driven capabilities and collaborative models to accelerate patient access to high-quality medicines worldwide.

🔵During the roundtable, experts shared insights on how new productivity drivers—biotech innovation, digitalized R&D, and Intelligent management—are reshaping the industry. They noted that Chinese pharma companies must strengthen differentiation, long-term strategy, and ex*****on to succeed globally.

🚀This forum not only fostered valuable exchanges but also underlined Kexing’s commitment to its “Innovation + Internationalization” strategy. Moving forward, Kexing will continue to collaborate with international partners, expand into overseas markets, and deliver broader therapeutic options to patients worldwide.

04/09/2025

📢First Patient Dosed in Phase II Trial of Fc-fusion Long-acting Growth Hormone (GB08)

🎖Recently, Kexing Biopharm’s subsidiary Kexing Biopharm (Shenzhen) has successfully completed the first patient dosing in the Phase II clinical study of FC human growth hormone (GB08), a novel Fc-fusion long-acting growth hormone developed for pediatric growth hormone deficiency (GHD).

🔎FC human growth hormone (GB08) applies Fc-fusion protein technology, combining the human growth hormone gene with the IgG4 Fc fragment to create a homodimer structure. The key advantages include:
👉Lower immunogenicity, enhancing safety for children;
👉Extended half-life, enabling less frequent dosing;
👉Improved treatment adherence and patient acceptance.

🥼Results from the Phase I trial, previously published in the《European Journal of Endocrinology》, highlighted its favorable safety and pharmacological profile.

🌏With multiple innovative programs advancing in parallel, Kexing Biopharm continues to pursue its “Innovation + Internationalization” strategy, aiming to deliver accessible, high-quality therapies to patients worldwide.

01/09/2025

🎉Kexing Biopharm’s Sorafenib (Generic Drugs) Approved in Egypt

📢Kexing Biopharm announced that its in-licensed oncology therapy, Sorafenib tablets (Generic Drugs), has been approved by the Egyptian Drug Authority, marking another milestone in the company’s commercialization strategy in the MENA region.

🌟Sorafenib is a globally recognized targeted therapy, widely used in the treatment of liver, kidney, and other cancers. The approval in Egypt will improve accessibility for local patients and provide new treatment options.

🌍As one of the largest healthcare markets in Africa and the Middle East, Egypt plays a strategic role in connecting regional pharmaceutical networks. Kexing has already established a subsidiary and built a local team in Egypt, ensuring faster market entry for high-quality medicines.

🚀This approval not only strengthens Kexing’s presence in Egypt but also reflects its “Global Selection + Global Coverage” strategy. Moving forward, Kexing will continue advancing its portfolio of biosimilars, complex formulations, and innovative drugs, reinforcing its transformation into a globally competitive biopharmaceutical company.

28/08/2025

🌏Strengthening Global Footprint｜Kexing Biopharm Expands International Presence🌏

👉While innovation fuels Kexing’s internal momentum, internationalization drives its global growth. Kexing Biopharm has established a comprehensive global marketing network and built localized teams across key regions, including the EU, Latin America, Southeast Asia, and MENA.

🙌Through partnerships and industry alliances, Kexing actively contributes to shaping a more collaborative and open biopharma ecosystem. This strategy not only accelerates product entry into international markets but also supports the broader “Go Global” movement of China’s pharmaceutical industry.

🎈Moving forward, Kexing will continue advancing its “Global Selection + Global Coverage” strategy, reinforcing the combined path of innovation and internationalization to deliver broader treatment options for patients worldwide.

Address

The 31 Floor，Huarun Center Building，Lixia District
Jinan
250000

Opening Hours

Monday	08:30 - 17:30
Tuesday	08:30 - 17:30
Wednesday	08:30 - 17:30
Thursday	08:30 - 17:30
Friday	08:30 - 17:30

Website

https://www.kexingbiopharm.com/

Alerts

Be the first to know and let us send you an email when Kexing Biopharm Co.,Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Jinan?